ProQR Therapeutics N.V.
ProQR Therapeutics N.V. (PRQR) Revenue
Annual & quarterly revenue history · segment & region breakdown
PRQR · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsProQR Therapeutics N.V. trailing twelve-month (TTM) revenue is $0.01B, a decrease of 19.18% year-over-year from $0.02B in FY2025.
Revenue trend
2025 – 2013 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.02B | -$0.00B | -19.18% |
| 2024-12-31 | $0.02B | +$0.01B | +190.22% |
| 2023-12-31 | $0.01B | +$0.00B | +81.25% |
| 2022-12-31 | $0.00B | +$0.00B | +169.21% |
| 2021-12-31 | $0.00B | +$0.00B | +29.74% |
| 2020-12-31 | $0.00B | -$0.00B | -46.77% |
| 2019-12-31 | $0.00B | -$0.00B | -60.88% |
| 2018-12-31 | $0.00B | +$0.01B | — |
| 2017-12-31 | $-0.00B | -$0.00B | -167.00% |
| 2016-12-31 | $0.00B | -$0.01B | -75.74% |
Compare revenue vs peers
BiotechnologyCompare PRQR revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income ProQR Therapeutics N.V. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
ProQR Therapeutics N.V. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in EUR.
Data sourced from ProQR Therapeutics N.V.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
PRQR revenue · 4 questionsPRQR's trailing twelve-month (TTM) revenue is $0.01B. That is a decrease of 19.18% year-over-year from $0.02B in FY2025.
▸ Source: FMP · ProQR Therapeutics N.V. SEC filings · GAAP · ProQR Therapeutics N.V. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026